Intellia Therapeutics Inc（股票代码：NTLA）今日盘前股价大幅上涨5.28%，引起了市场的广泛关注。
消息面上，公司针对遗传性血管水肿的候选疗法Lonvoguran Ziclumeran（Lonvo-Z）在三期临床试验中取得了突破性成功。试验不仅达到了主要研究终点，还达成了全部关键次要终点。数据显示，单次给药后，与安慰剂相比，该疗法在六个月内将疾病发作频率降低了87%，并使大多数受试者在长达六个月内无需应对急性发作且摆脱了持续治疗的需求。
与此同时，Intellia Therapeutics已正式启动向美国食品药品监督管理局（FDA）滚动提交Lonvo-Z生物制品许可申请的程序，旨在将其作为一次性疗法推向市场。这一系列积极的研发与监管进展，标志着全球首个体内基因编辑疗法迈向商业化的重要一步，显著增强了市场对公司未来前景的信心，从而推动了股价在盘前交易时段走强。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.